Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in Rest of World: $1,483M in FY2025, up 42.5% from a year earlier.
Latest, FY2025
1,483
Period ended Dec 31, 2025
Change on a year earlier
+42.5%
1,041 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Kesimpta | Neuroscience | Relapsing forms of multiple sclerosis (MS) | 2 943 | 35 | 1 483 | 42 | 39 | 4 426 | 37 | 36”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in Rest of World ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,483 | +42.5% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,041 | +61.9% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 643 | +276.0% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 171 | – | Novartis Form 6-K (0001370368-23-000008) ↗ |
Breakdown
What makes up net Sales in Rest of World
Cite this data
StockData. (2026). Novartis Net Sales in Rest of World ($M), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kesimpta-row-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.